GLOBAL NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET FORECAST 2021-2028
Published
Apr 05 2021 at 8:19 AM GMT
Key
Points
Points
- New York, April 05, 2021 (GLOBE NEWSWIRE) -- Reportlinker com announces the release of the report "GLOBAL NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET FORECAST 2021-2028" - https://www reportlinker com/p06010867/'utm_source=GNW MARKET INSIGHTSNon-alcoholic steatohepatitis (NASH), a highly destructive form of non-alcoholic fatty liver disease (NAFLD), often develops into more severe disorders, like hepatocellular carcinoma and cirrhosis.
- As a result, NASH is projected to surpass the hepatitis C virus infection and become the leading cause of liver transplantation, worldwide, over the upcoming decade.
- As these diseases progress, the liver experiences fibrosis and scarring, ultimately leading to cirrhosis.
- Liver fibrosis is likely to result in permanent organ damage, progress to hepatocellular carcinoma, and liver failure.
- Obesity is a well-recognized epidemic, globally.
Trending
Stats
- Published Apr 5, 2021 8:19 AM GMT